Droperidol Drug Cleared for Generics, No Drama Here
Published Date: 4/1/2026
Notice
Summary
The FDA has decided that INAPSINE (droperidol) injection wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can keep being approved and sold as long as they follow the rules. Patients and healthcare providers can keep trusting this medicine without worry, and drug makers can continue their work without delays or extra costs.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Generics Stay Approvable; Market Access Preserved
The FDA determined that INAPSINE (droperidol) injection, 2.5 mg/mL (NDA 016796, initially approved June 11, 1970), was not withdrawn for reasons of safety or effectiveness. Because of that determination, FDA will not start procedures to withdraw approval of existing ANDAs that refer to this product and may continue to approve new ANDAs that rely on this listed drug as long as they meet legal and regulatory requirements.
Possible Labeling Updates for ANDA Applicants
The FDA said it may advise ANDA applicants to revise the product labeling for INAPSINE (droperidol) injection to meet current standards. If FDA determines labeling should be revised, ANDA applicants will be asked to submit updated labeling.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-06313 — Kitchen Appliance Shelving and Racks From China
The U.S. International Trade Commission decided to keep special taxes on kitchen appliance shelving and racks from China because removing them could hurt American businesses. This means importers will still pay extra duties, helping protect U.S. manufacturers. The decision was finalized on March 30, 2026, so these rules stay in place for now.
Next: 2026-06315 — Notice of Proposed Reinstatement of BLM New Mexico Terminated Oil and Gas Lease: NMNM141519
Enrique A. Cantu asked to bring back his New Mexico oil and gas lease NMNM141519, which was ended before. The Bureau of Land Management agrees to reinstate it starting January 1, 2022, with updated rental fees of $20 per acre and a 20% royalty. This means Cantu can keep drilling under new terms, as long as he sticks to the rules and pays up.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in